Re-discovery of PF-3845 as a new chemical scaffold inhibiting phenylalanyl-tRNA synthetase in Mycobacterium tuberculosis

Heng Wang, Min Xu, Curtis A. Engelhart, Xi Zhang, Baohua Yan, Miaomiao Pan, Yuanyuan Xu, Shilong Fan, Renhe Liu, Lan Xu, Lan Hua, Dirk Schnappinger, Shawn ChenbioRxiv 2020 · DOI

TL;DR

Researchers have identified PF-3845, a known human enzyme inhibitor, as a potent new chemical scaffold targeting phenylalanyl-tRNA synthetase (PheRS) in Mycobacterium tuberculosis (Mtb). This discovery offers a promising avenue for developing novel antibiotics against drug-resistant tuberculosis, with PF-3845 demonstrating selective inhibition of the bacterial enzyme and in vitro activity against Mtb.

What Problem Does This Paper Address?

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a major global health threat, exacerbated by the rise of drug-resistant strains. The urgent need for new antibiotics necessitates the identification of novel drug targets and chemical scaffolds. Phenylalanyl-tRNA synthetase (PheRS) is an essential bacterial enzyme involved in protein synthesis, and its significant differences from human counterparts make it an attractive target for selective antibacterial drugs. However, finding potent and selective inhibitors for Mtb PheRS has been challenging. This paper addresses this by screening a library of existing bioactive compounds to find new inhibitors of Mtb PheRS, aiming to identify a novel chemical scaffold with potential for TB drug development.

Methods

The study employed a multi-pronged approach:

  • High-Throughput Screening (HTS): A library of 2148 bioactive compounds was screened against Mtb PheRS using an ATP consumption assay (Kinase-Glo).
  • Enzyme Kinetics: Detailed kinetic studies were performed to characterize the inhibition mechanism of identified hits, including determining inhibition constants (Kᵢ) and modes of inhibition (competitive, non-competitive, etc.) with respect to different substrates (L-Phe, ATP, tRNA).
  • Biochemical Assays: Various assays were used to measure enzyme activity, including pyrophosphate (PPi) production and malachite green assays.
  • Crystallography: The crystal structures of Mtb PheRS, both apo (unbound) and in complex with inhibitors (GDI05-001 and PF-3845), were determined at high resolution (2.3-2.83 Å). This allowed for detailed visualization of inhibitor binding modes.
  • Protein Structural Modelling: Computational modeling was used to predict potential binding conformations of PF-3845.
  • Cellular Assays: The in vitro growth inhibition of Mtb strains (wild-type H37Rv and a modified pheS-FDAS strain) by PF-3845 was assessed using microplate alamarBlue assays (MABA). Cytotoxicity against mammalian cell lines was also evaluated.
  • Sequence Alignment and Structural Comparison: Mtb PheRS was compared to human cytoplasmic and mitochondrial PheRSs to understand the structural basis for selectivity.

Datasets

  • Selleck-2148 Bioactive Compound Library: A library of 2148 small molecules with validated biological and pharmacological activities was used for the HTS.
  • Publicly Available Structures: Structures of related enzymes (e.g., E. coli PheRS, human FARS) were used for comparative analysis and structural modeling.
  • Newly Determined Crystal Structures: The study generated novel crystal structures of Mtb PheRS in complex with GDI05-001 and PF-3845, which are deposited in the Protein Data Bank (PDB) under accession codes 7DAW, 7DB7, and 7DB8.

Key Insights and Ideas

  • Repurposing a Known Inhibitor: PF-3845, originally identified as an inhibitor of human fatty acid amide hydrolase (FAAH), was unexpectedly found to be a potent inhibitor of Mtb PheRS. This highlights the potential of repurposing existing drugs or known bioactive scaffolds for new therapeutic applications.
  • Novel Binding Mode: The crystal structure of Mtb PheRS complexed with PF-3845 revealed a unique binding mode. PF-3845 occupies both the phenylalanine (Phe) pocket and the ATP pocket, a characteristic of "bi-substrate" inhibitors. This dual occupancy is facilitated by a sulfate ion, which plays a crucial role in bridging interactions and stabilizing the binding.
  • Sulfate Ion's Critical Role: The presence of a sulfate ion was found to enhance PF-3845's binding affinity and make it a true bi-substrate competitive inhibitor. This is a notable observation, as sulfate ions are not typically considered direct participants in ligand binding in this manner.
  • Structural Basis for Selectivity: Significant differences in the amino acid binding pockets between Mtb PheRS and human PheRS (hFARS1 and hFARS2) were identified. Specifically, a smaller residue (V286) in Mtb PheRS compared to larger residues (F438, M258) in human PheRS creates a larger amino acid pocket in the bacterial enzyme, which PF-3845 exploits. This structural disparity explains the observed selectivity of PF-3845 for the bacterial enzyme.
  • On-Target Activity in Mtb: The increased potency of PF-3845 against a modified Mtb strain (pheS-FDAS) suggests that the compound is indeed acting on its intended target within the mycobacterial cell.

Key Results

  • Potent Inhibition: PF-3845 inhibited Mtb PheRS with a Kᵢ of approximately 0.73 µM.
  • In Vitro Activity: PF-3845 inhibited the in vitro growth of Mtb H37Rv at a concentration of approximately 24 µM.
  • Selective Inhibition: PF-3845 did not inhibit human cytoplasmic or mitochondrial PheRSs at concentrations up to 200 µM.
  • Novel Inhibitor Class: PF-3845 represents the first identified non-nucleoside bi-substrate competitive inhibitor of bacterial PheRS.
  • Improved Potency in Modified Strain: The potency of PF-3845 increased against Mtb pheS-FDAS, indicating on-target activity in whole cells.

Limitations and Future Work

  • Cytotoxicity: While PF-3845 shows selectivity for the bacterial enzyme, its cytotoxicity against mammalian cell lines is a concern. The CC₅₀ values are relatively close to or even lower than the MIC values for Mtb, suggesting that further medicinal chemistry efforts are needed to improve its therapeutic index.
  • Medicinal Chemistry Optimization: The authors suggest that further elaboration of the piperidine-piperazine urea moiety of PF-3845 could lead to potential antibacterial leads with improved cellular selectivity. They also propose minimizing the trifluoromethyl-pyridinyl group to reduce binding to the auxiliary pocket.
  • Further Mechanistic Studies: While the binding mode and kinetics are well-characterized, further studies could explore the precise implications of the sulfate ion's role and investigate potential resistance mechanisms.
  • In Vivo Efficacy: The study focused on in vitro and biochemical assays. Future work would involve evaluating the in vivo efficacy and pharmacokinetic properties of PF-3845 or its optimized derivatives in animal models of TB.

Summary updated

Abstract

Abstract Mycobacteria tuberculosis (Mtb) remains the deadliest pathogenic bacteria worldwide. The search for new antibiotics to treat drug-sensitive as well as drug-resistant tuberculosis has become a priority. The essential enzyme phenylalanyl-tRNA synthetase (PheRS) is an antibacterial drug target because of the large differences between bacterial and human PheRS counterparts. In a high-throughput screening of 2148 bioactive compounds, PF-3845, which is a known inhibitor of human fatty acid amide hydrolase (FAAH), was identified inhibiting Mtb PheRS at K i ∼0.73 ± 0.055 µM. The inhibition mechanism was studied with enzyme kinetics, protein structural modelling and crystallography, in comparison to a PheRS inhibitor of the noted phenyl-thiazolylurea-sulfonamide class. The 2.3-Å crystal structure of Mtb PheRS in complex with PF-3845 revealed its novel binding mode, in which a trifluoromethyl-pyridinylphenyl group occupies the Phe pocket while a piperidine-piperazine urea group binds into the ATP pocket through an interaction network enforced by a sulfate ion. It represents the first non-nucleoside bi-substrate competitive inhibitor of bacterial PheRS. PF-3845 inhibits the in vitro growth of Mtb H37Rv at ∼24 µM, and the potency of PF-3845 increased against Mtb pheS-FDAS, suggesting on target activity in mycobacterial whole cells. PF-3845 does not inhibit human cytoplasmic or mitochondrial PheRSs in biochemical assay, which can be explained from the crystal structures. Further elaboration of the piperidine-piperazine urea moiety by medicinal chemistry effort will produce potential antibacterial lead with improved selectivity on the cellular level.
BibTeX
@misc{wang2020re,
  author = {Heng Wang and Min Xu and Curtis A. Engelhart and Xi Zhang and Baohua Yan and Miaomiao Pan and Yuanyuan Xu and Shilong Fan and Renhe Liu and Lan Xu and Lan Hua and Dirk Schnappinger and Shawn Chen},
  title = {{Re-discovery of PF-3845 as a new chemical scaffold inhibiting phenylalanyl-tRNA synthetase in <i>Mycobacterium tuberculosis</i>}},
  year = {2020},
  doi = {10.1101/2020.10.27.357681},
  howpublished = {bioRxiv},
}
Figure